Quality of Pharma-sponsored Health Information on the Internet

What is the attitude of pharmaceutical professionals regarding the quality of pharma-sponsored health information on the Net? Does the industry perceive a problem in this area? To help answer this question, a survey - Quality of Pharma-Sponsored Health Information on the Internet - was sponsored by the Internet Healthcare Coalition in conjunction with the Pharma Marketing Network (PMN) and was hosted by PollingPharma on their web site (www.pollingpharma.com) during the month of January, 2003

OpEd: More Permission, More Data, Better Marketing?

What's the connection between the effectiveness of DTC advertising, patient-level data vs. physician-level data, and out-of-the-box marketing? Adoption of these new techniques and data sources by pharmaceutical marketers depends on good education, vendor cooperation, and success stories to prove that the effort is worth it

Top Companies, Classes, and Products in the DTC Space

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Top Companies, Classes, and Products in the DTC Space

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Has DTC Spending Peaked?

There are powerful lobbyists, including employers, insurers, AARP, and Public Citizen, with an anti-DTC agenda in Washington. The criticism takes many forms - increases in drug prices, increase in inappropriate prescribing, etc. Republicans have gained control, but some committee chairs are DTC critics.

Online and Offline Professional and Consumer Marketing

Attending conferences like the recent Pharmaceutical Marketing Global Summit provides tidbits of information about how pharma marketing practices need to evolve. Although the advice from one expert often conflicts with that of another, and sometimes the advice is self-serving, some suggestions seem to ring true and have universal support.

Impact of DTC Advertising of the Doctor-Patient Relationship

This article reviews a presentation by Kathryn Aikin of DDMAC/FDA in which she disclosed preliminary results from the FDA's Physician Survey, which looked at the impact of DTC advertising on the doctor-patient relationship

Top Companies, Classes, and Products in the DTC Space

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Top Companies, Classes, and Products in the DTC Space

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Texas Medical Privacy Act: A Wolf in Sheep’s Clothing?

Anyone who is even a casual reader of Pharma Marketing News knows that we support consumers' right to privacy and believe that pharmaceutical marketers need to beef up their privacy policies if they hope to improve consumer trust. So it may surprise you when we say that a new Texas privacy law goes too far in its apparent zeal to protect patients' privacy. In fact, we believe that this law's real purpose is to limit the ability of pharmaceutical companies and their agents to communicate product information directly to consumers in Texas. The privacy law we talking about is the Texas Medical Privacy Act (SB 11). SB 11 is known in some quarters as 'super HIPAA' because it applies super-stringent HIPAA-like privacy regulations to pharmaceutical companies, their advertising/ marketing agencies and other entities - even individuals. A covered entity under SB 11 is any person who assembles, collects, analyses, uses, evaluates, stores, or transmits protected health information. The law becomes effective in Texas September 1, 2003.